Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

The administration, which is set to cut the subsidy for the drug benefit program by 40%, says it will negotiate with insurers to ease the financial strain to the millions of seniors on the plan. Plus, ...